Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 181

Results For "development"

3457 News Found

Strides and Orbicular enter into a strategic partnership to develop a range of nasal sprays
News | May 04, 2023

Strides and Orbicular enter into a strategic partnership to develop a range of nasal sprays

The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m


Indoco receives EIR for its Plant I manufacturing facility in Goa
Drug Approval | May 04, 2023

Indoco receives EIR for its Plant I manufacturing facility in Goa

Indoco expects this change in compliance status to pave the way for approvals of ANDAs submitted from this site.


Astec LifeSciences FY23 PAT declines to Rs. 25.6 Cr
News | May 03, 2023

Astec LifeSciences FY23 PAT declines to Rs. 25.6 Cr

The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year


USFDA Advisory Committee votes  n Lynparza plus Abiraterone and Prednisone  for prostate cancer
Drug Approval | May 03, 2023

USFDA Advisory Committee votes n Lynparza plus Abiraterone and Prednisone for prostate cancer

The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients


CPHI & PMEC China 2023 to see surge from pent up international ingredients demand
News | May 03, 2023

CPHI & PMEC China 2023 to see surge from pent up international ingredients demand

China recorded unprecedented improvement in its API manufacturing score in the 2022 end of year CPHI Survey


Lilly's Lebrikizumab shows improved face or hand dermatitis
Clinical Trials | May 02, 2023

Lilly's Lebrikizumab shows improved face or hand dermatitis

Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients


CHMP recommends EU approval of Roche’s fixed-duration Columvi for large B-cell lymphoma
Drug Approval | May 02, 2023

CHMP recommends EU approval of Roche’s fixed-duration Columvi for large B-cell lymphoma

Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma


Aptar Digital Health and Healint collaborate for Central Nervous System
Digitisation | May 01, 2023

Aptar Digital Health and Healint collaborate for Central Nervous System

The partnership will capitalize on the combined capabilities of the two organizations


Atul appoints Rangaswamy Iyer as Independent Director
People | April 29, 2023

Atul appoints Rangaswamy Iyer as Independent Director

The appointment is effective from May 01, 2023 for five years


Evonik starts construction of new U.S. facility for pharmaceutical lipids
News | April 29, 2023

Evonik starts construction of new U.S. facility for pharmaceutical lipids

Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness